Rohto's Japan profit rises 8% after April's Hada Labo price increase, even as Melano CC and sunscreen lose ground
Rohto Pharmaceutical's domestic skincare business grew profit faster than sales in its first half, largely because April's price rise on Hada Labo (肌ラボ) stuck -- even as long-running hits Melano CC (メラノCC) and its Skin Aqua (スキンアクア) sunscreen lost sales to competition, a split that shows pricing power concentrated in a few of Rohto's biggest names rather than across its whole shelf.
Rohto Pharmaceutical Co., Ltd. (ロート製薬) said on 12 November that group revenue for the six months to 30 September 2026 rose 9.0% to ¥179.01bn and operating profit rose 8.5% to ¥20.95bn, while net profit fell 6.5% to ¥16.50bn against a one-off dividend gain booked a year earlier.